Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: Clinical outcomes

Nephrology Dialysis Transplantation

Volumn 23, Issue 4, 2008, Pages 1233-1240

  Kane, Garvan C ^a   Stanson, Anthony W ^a   Kalnicka, Dita ^a,b   Rosenthal, David W ^a   Lee, Christine U ^a   Textor, Stephen C ^a   Garovic, Vesna D ^a,c  

^a Mayo Clinic   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

^c MAYO CLINIC   (United States)

Author keywords

Atherosclerotic renal artery stenosis; Contrast media; Contrast nephropathy; Gadolinium angiography; Ischaemic nephropathy; Percutaneous transluminal angioplasty

Indexed keywords

GADODIAMIDE; GADOLINIUM; GADOTERIDOL; IODINE; IODIXANOL; IOHEXOL; CONTRAST MEDIUM; CREATININE; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE; HETEROCYCLIC COMPOUND; IODOBENZOIC ACID DERIVATIVE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NEPHROGENIC FIBROSING DERMOPATHY; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; ATHEROSCLEROSIS; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; HOSPITALIZATION; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; RADIOGRAPHY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

AGED; ANGIOGRAPHY, DIGITAL SUBTRACTION; ANGIOPLASTY, BALLOON; ATHEROSCLEROSIS; CONTRAST MEDIA; CREATININE; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; GADOLINIUM DTPA; HETEROCYCLIC COMPOUNDS; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; IOHEXOL; MALE; MINNESOTA; ORGANOMETALLIC COMPOUNDS; RENAL ARTERY OBSTRUCTION; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIIODOBENZOIC ACIDS;

EID: 42949115533     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm725     Document Type: Article

References (42)

1. Franklin SS, Young JD Jr, Maxwell MH et al. Operative morbidity and mortality in renovascular disease. JAMA 1975; 231: 1148-1153
2. Weibull H, Bergqvist D, Bergentz SE et al. Percutaneous transluminal renal angioplasty versus surgical reconstruction of atherosclerotic renal artery stenosis: a prospective randomized study. J Vasc Surg 1993; 18: 841-850; discussion 850-852
3. Gami AS, Garovic VD. Contrast nephropathy after coronary angiography. Mayo Clin Proc 2004; 79: 211-219
4. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 2006; 113: 1799-1806
5. McCullough PA, Wolyn R, Rocher LL et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-375
6. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264
7. Solomon R, Werner C, Mann D et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents [see comment] N Engl J Med 1994; 331: 1416-1420
8. Stone GW, McCullough PA, Tumlin JA et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290: 2284-2291
9. Merten GJ, Burgess WP, Gray LV et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291: 2328-2334
10. Tepel M, van der Giet M, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-184
11. Mueller C, Buerkle G, Buettner HJ et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty [see comment]. Arch Intern Med 2002;162: 329-336
12. Bouiller M, Flamant M, Dautheville S et al. Utilisation du Gadolinium comme produit de contraste au cours d'une angioplastie des arteres renales. J Mal Vasc 1998; 23: 201-203
13. Harb TS, Laird JR, Dieter RS et al. Renal artery stenting using gadodiamide arteriography in patients with baseline renal insufficiency. J Endovasc Ther 2004; 11: 553-559
14. Spinosa DJ, Matsumoto AH, Angle JF et al. Use of gadopentetate dimeglumine as a contrast agent for percutaneous transluminal renal angioplasty and stent placement. Kidney Int 1998; 53: 503-507
15. Spinosa DJ, Matsumoto AH, Angle JF et al. Renal insufficiency: usefulness of gadodiamide-enhanced renal angiography to supplement CO2-enhanced renal angiography for diagnosis and percutaneous treatment. Radiology 1999; 210: 663-672
16. Spinosa DJ, Matsumoto AH, Angle JF et al. Safety of CO(2)-and gadodiamide-enhanced angiography for the evaluation and percutaneous treatment of renal artery stenosis in patients with chronic renal insufficiency. AJR Am J Roentgenol 2001;176: 1305-1311
17. Sarkis A, Badaoui G, Slaba S et al.Gadolinium-based coronarography in a patientwith renal failure: first clinical report. Catheter Cardiovasc Interv 2001; 54: 68-69
18. Robert A, Bonneville F, Miralbes S et al. Le gadolinium en arteriographie et en radiologie interventionnelle: a propos de 39 patients. J Radiol 2002; 83: 1759-1763
19. Zeller T, Muller C, Frank U et al. Gadodiamide as an alternative contrast agent during angioplasty in patients with contraindications to iodinated media. J Endovasc Ther 2002; 9: 625-632
20. Amar AP, Larsen DW, Teitelbaum GP. Percutaneous carotid angioplasty and stenting with the use of gadolinium in lieu of iodinated contrast medium: technical case report and review of the literature. Neurosurgery 2001; 49: 1262-1265; discussion 1265-1266
21. Rieger J, Sitter T, Toepfer M et al. Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 2002; 17: 824-828
22. Fobbe F, Wacker F, Wagner S. Arterial angiography in high-kilovoltage technique with gadolinium as the contrast agent: first clinical experience. Eur Radiol 1996; 6: 224-229
23. Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). J Am Coll Cardiol 2006; 47: e1-e192
24. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147
25. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572
26. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
27. Textor SC, Wilcox CS. Renal artery stenosis: a common, treatable cause of renal failure? Annu Rev Med 2001; 52: 421-442
28. Garovic VD, Kane GC, Schwartz GL. Renovascular hypertension: balancing the controversies in diagnosis and treatment. Cleve Clin J Med 2005; 72: 1135-1144
29. Dorros G, Jaff M, Mathiak L, He T, Multicenter Registry P. Multicenter Palmaz stent renal artery stenosis revascularization registry report: four-year follow-up of 1,058 successful patients. Catheter Cardiovasc Interv 2002; 55: 182-188
30. Isles CG, Robertson S, Hill D. Management of renovascular disease: a review of renal artery stenting in ten studies. Q J Med 1999; 92: 159-167
31. van de Ven PJ, Kaatee R, Beutler JJ et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial. Lancet 1999; 353: 282-286
32. Hatrick AG, Jarosz JM, Irvine AT. Gadopentate dimeglumine as an alternative contrast agent for use in interventional procedures. Clin Radiol 1997; 52: 948-952
33. Sarkis A, Badaoui G, Slaba S et al. Gadolinium-based coronarography in a patientwith renal failure: first clinical report. Catheter Cardiovasc Interv 2001; 54: 68-69
34. Bokhari SW, Wen YH, Winters RJ. Gadolinium-based percutaneous coronary intervention in a patient with renal insufficiency. Catheter Cardiovasc Interv 2003; 58: 358-361
35. Robert A, Bonneville F, Miralbes S et al. Gadolinium in arteriography and interventional radiology: 39 patients. J Radiol 2002; 83: 1759-1763
36. Prince MR, Erel HE, Lent RW et al. Gadodiamide administration causes spurious hypocalcaemia. Radiology 2003; 227: 639-646
37. Prince MR, Choyke PL, Knopp MV. More on pseudohypocalcaemia and gadolinium-enhanced MRI. N Engl J Med 2004; 350: 87-88
38. Grobner T. Gadolinium - a specific trigger for development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-1108
39. Garovic VD, Helgen KE. Nephrogenic fibrosing dermopathy. N Engl J Med 2007; 357
40. Parazella MA, Rodby RA. Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney disease. Am J Med 2007; 120: 561-562
41. Swaminathan S, Horn T, Pellowski D et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 2007; 357: 720-722
42. Swaminathan S, Ahmed I, McCarthy JT et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006; 145: 234-235